Pacific Ethanol California (NASDAQ: PEIX) $0.87 Traders scooped up shares for Pacific Ethanol California as it popped 2.52% with a healthy volume of 725K, which is twice as much as the average volume. High volume often signals a change in trends. Shares of Pacific Ethanol are currently trading above their 50-day moving average (MA) of $0.78 and above their 200-day MA of $0.79. Stock is currently in an uptrend as it continues to reach new highs.
Pacific Ethanol, Inc. produces and sells ethanol and its co-products in the western United States, primarily in California, Nevada, Arizona, Oregon, Colorado, Idaho, and Washington. It also provides transportation, storage, and delivery of ethanol through third-party service providers. The companys co-products comprise wet distillers grains. It sells ethanol to gasoline refining and distribution companies, and wet distillers grains to dairy operators and animal feed distributors. The company was founded in 2003 and is headquartered in Sacramento, California.
USA Technologies (NASDAQ: USAT) $1.92 Back on January 24th the stock was showing weakness, but it has rallied up to $1.92 and has leveled off since then at $1.80 range. Today it showed a gain of 2% but began selling off earlier in the day. USAT continues to show strength with a moderate volume of an average of 700K shares.
USA Technologies, Inc. supplies cashless, remote management, reporting, and energy management solutions to the unattended point of sale market principally in the United States. The companys network devices and associated services enable the owners and operators of distributed assets, such as vending machines, kiosks, personal computers, photocopiers, and laundry equipment the ability to monitor, control, and report on the results of the distributed assets, as well as the ability to offer the customers cashless payment options.
Entest BioMedical Inc. (OTC: ENTB) $3.87 Stock increased by 7.5% with a relatively low volume of 30K. It is something to keep an eye on especially if the volume starts steadily increasing. Company has been diligently persistent in attempting to grow its revenues, but the lack of liquidity at this point keeps investors at bay. Recently CEO announced that they plan to acquire additional clinics and move things forward on ImenVax 10 Dog Safe Study.
Entest BioMedical Inc. is a developer of veterinary that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.
ICAgen Inc. (OTC: ICGN) $2.90 The stock has been losing ground with a 6.7% loss so far and an average volume of 303K. We spotted this stock back on Jan. 12th when it was trading in the range of $1.90-$1.95, and advised to sell and take some off the table. Now the stock has been under selling pressure as it is trying to level off before it continues its run. Buy incrementally and use caution with this one.
Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. Its drug candidates include ICA-105665, which has completed Phase I multiple ascending dose study in healthy volunteers and epilepsy patients for epilepsy and neuropathic pain; and Senicapoc, a small molecule potassium channel inhibitor under the Phase II proof-of-concept clinical trials for the treatment of asthma.
Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) $1.46 An uptrend was spotted on this stock on Dec. 17th, 2010, and as of then, this puppy returned 19%. With a beta of 1.57, it makes this company a decent stock to buy, but not too speculative considering its risk/reward ratio. Today it surged another 6.72% with an increased volume of 1.1 million.
Alexza Pharmaceuticals, Inc., a development stage company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system that vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: PennyTrader.com has not been compensated for any stocks listed in this stock news report